+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Eliciting patients' preferences for adjuvant chemotherapy in breast cancer: development and validation of a bedside decision-making instrument in a French Regional Cancer Centre



Eliciting patients' preferences for adjuvant chemotherapy in breast cancer: development and validation of a bedside decision-making instrument in a French Regional Cancer Centre



Health Expectations 3(2): 97-113



In developed countries, the physician-patient relationship is moving from a paternalistic model to new decision-making models that take patient preferences into account. OBJECTIVES: Our aim was to develop a Decision Board (DB) and to test its acceptability in a French Regional Cancer Centre regarding the decision on whether or not to use chemotherapy after surgery in postmenopausal women with breast cancer. This paper presents the development process for this instrument and reports the pretesting phase, as well as the corresponding results. METHODS: A working group was created with oncologists, psychologists and economists. Following the first phase, i.e. the development process, a first version of the instrument was presented to health professionals. Their feedback led to important modifications of the instrument. The DB was then presented to experienced patients, which resulted in slight changes. The second phase consisted of pretesting the comprehension, internal and across-time consistency of the DB on healthy volunteers. RESULTS: The DB was pretested in a group of 40 healthy volunteers. Eighteen respondents chose chemotherapy and 22 chose not to have chemotherapy. Comprehension rates were very high (>/=87.5%). Internal consistency was assessed considering option attitudes based on outcomes and option attitudes based on process. Women shifted their choices in a predictable way. Across-time consistency was appraised using the test-retest method with Visual Analog Scales. The Intraclass Correlation Coefficient was 0.97. DISCUSSION-CONCLUSION: Due to cultural differences, the DB developed in our French Cancer Centre is quite different from the DBs previously developed elsewhere. Our instrument showed good comprehension and consistency properties, which are corroborated by the DB literature. Whether our DB is acceptable for patients with breast cancer must still be tested. Patients' reactions will tell us which type of decision-making model is at work. Further research is needed in order to explore the shared decision-making process and clarify the concept.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045944951

Download citation: RISBibTeXText

PMID: 11281917


Related references

A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Annals of Internal Medicine 117(1): 53-58, 1992

A Discrete Choice Experiment For Engaging Patients In Reimbursement Decision Making: Patient Preferences On Adjuvant Chemotherapy In Breast Cancer. Value in Health 18(7): A470, 2015

Dissociation of decision making under ambiguity and decision making under risk in breast cancer patients receiving adjuvant chemotherapy: a neuropsychological study. Brain Research 1533: 63-72, 2013

Patient participation in medical decision-making: a French study in adjuvant radio-chemotherapy for early breast cancer. Annals of Oncology 11(1): 39-45, 2000

Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecologic Oncology 62(3): 329-335, 1996

Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey. Bulletin du Cancer 101(10): 918-924, 2014

Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making. Psycho-Oncology 22(12): 2729-2735, 2013

The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients. Annals of Oncology 19(7): 1213-1215, 2008

Shared decision-making in routine clinical practice: the example of breast cancer in a regional cancer centre in France. 2007

Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Supportive Care in Cancer 11(5): 313-320, 2003

Exploring Decision-Making about Neo-adjuvant Chemotherapy for Breast Cancer. Breast Journal 22(1): 133-134, 2016

Comparison of adjuvant chemotherapy versus loco-regional radiotherapy followed by adjuvant chemotherapy in breast cancer patients with 4 or more positive axillary nodes: A southeastern cancer study group study. International Journal of Radiation Oncology*biology*physics 17(Supp-S1): 180-0, 1989

Comparison of adjuvant chemotherapy versus loco regional radiotherapy followed by adjuvant chemotherapy in breast cancer patients with 4 or more positive axillary nodes a southeastern cancer study group study. International Journal of Radiation Oncology, Biology, Physics 17(Suppl. 1): 180, 1989

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care 11(5): 315-322, 2016

Decision-making role preferences of patients receiving adjuvant cancer treatment: a university of Rochester cancer center community clinical oncology program. Supportive Cancer Therapy 1(2): 119-126, 2008